Condition
Skin Kaposi Sarcoma
Total Trials
5
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
P 2 (5)
Trial Status
Completed3
Not Yet Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07539454Phase 2Not Yet Recruiting
Nirogacestat in Patients With Kaposi Sarcoma
NCT03601806Phase 2Completed
Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
NCT04577755Phase 2Active Not RecruitingPrimary
Pomalidomide Treatment in Patients With Kaposi Sarcoma
NCT03077451Phase 2Completed
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
NCT02799485Phase 2CompletedPrimary
sEphB4-HSA in Treating Patients With Kaposi Sarcoma
Showing all 5 trials